



ALZHEIMER'S DISEASE

- More than 5 million individuals in the United States are living with Alzheimer's disease.
- This is estimated to increase to approximately 15 million by 2050.

AGITATION IN ALZHEIMER'S DISEASE

- Up to 70% of patients experience symptoms of agitation or aggression (emotional distress, aggressive or disruptive behaviors, shouting and disinhibition).
- Agitation symptoms increase caregiver burden, decrease patient functioning, and can result in earlier nursing home placement and increased mortality risk.

AGITATION IN ALZHEIMER'S DISEASE REMAINS A CHALLENGE WITH NO APPROVED THERAPIES.

THE ACCORD STUDY IS INVESTIGATING A POTENTIAL TREATMENT.




ACCORD

Assessing Clinical Outcomes
in Alzheimer's Disease Agitation

STUDY DESIGN

Treatment Period: Up to 35 weeks



KEY ELIGIBILITY CRITERIA*

- 65-90 years of age, inclusive
- A probable diagnosis of Alzheimer's disease
- Symptoms of agitation or aggression resulting in distress in their home
- A supportive, consistent, and reliable caregiver willing to participate

*Other criteria apply.

Pharmacodynamic Synergy

MECHANISM OF ACTION	DM	BUP	AXS-05 (DM+BUP)
NMDA Receptor Antagonist	✓		✓
Sigma-1 Receptor Agonist	✓		✓
Norepinephrine Reuptake Inhibitor	✓	✓	✓
Serotonin Reuptake Inhibitor	✓		✓
Dopamine Reuptake Inhibitor		✓	✓
Nicotinic ACh Receptor Antagonist		✓	✓

DM = Dextromethorphan; BUP = Bupropion. ✓ Present

AXS-05

AXS-05 is a novel fixed-dose combination of bupropion and dextromethorphan.

Inhibits DM metabolism

